Sanofi Vaccines US Inc.

Sanofi Vaccines US Inc., a division of Sanofi Pasteur Inc., is a foreign-owned pharmaceutical manufacturer that supplies vaccines and biological products to the federal government as a prime contractor across nearly all federal agencies, with no subcontracting activity in the award footprint. The vendor competes in the full-and-open federal marketplace with no set-aside designations and operates from Swiftwater, Pennsylvania, its primary U.S. manufacturing facility.

Sanofi Vaccines US Inc. delivers concrete vaccine products and pandemic preparedness manufacturing services grounded in a diverse federal award portfolio. Capability work spans routine seasonal influenza immunization procurement, pediatric and adult COVID-19 vaccines, respiratory syncytial virus (RSV) vaccines, hepatitis, meningococcal, pneumococcal, typhoid, polio, tetanus, and human papillomavirus vaccines for federal correctional facilities, the Veterans Health Administration, Department of Defense personnel, Indian Health Service populations, and CDC Vaccines for Children program beneficiaries. Representative prime awards include a $24.87 million delivery order from the Office of the Assistant Secretary for Preparedness and Response for a clinical trial of Matrix-M adjuvant in combination with egg-based A/Astrakhan H5N8 influenza vaccine (September 2025), a $79.84 million cost-plus-fixed-fee contract for maintaining embryonated egg supply to support non-seasonal pandemic vaccine production (February 2025), and a $2.92 million Department of Defense Medical Supply Chain delivery order for influenza virus vaccine (February 2026). The vendor also holds a $60.2 million (combined ceiling) contract for travel vaccines under a blanket purchase agreement call issued by an unnamed federal agency (January 2026).

Customer concentration is extreme and bimodal. By award count, the top five agencies represent 37% of all awards: Department of the Navy Bureau of Medicine and Surgery (1,217 awards, $33.2 million combined potential value), Defense Logistics Agency Troop Support Medical (728 awards, $229.4 million), Department of the Army (449 awards, $798 thousand), Defense Logistics Agency (335 awards, $11.4 million), and Department of Veterans Affairs (277 awards, $1.2 million). By potential value, the ranking shifts dramatically toward large IDIQs with civilian agencies: CDC Pittsburgh (75 awards, $34.65 billion combined potential value), Office of the Assistant Secretary for Preparedness and Response (104 awards, $24.13 billion), Veterans Health Administration Veterans Integrated Service Network 12 (114 awards, $2.2 billion), Defense Logistics Agency Troop Support Medical (728 awards, $229.4 million), and Indian Health Service (50 awards, $34.8 million). The vendor's $144.14 billion combined potential value across 8,204 total awards reflects its role as a critical supplier across the federal vaccine procurement landscape; the 13% obligated-to-potential ratio indicates substantial frame contracts and indefinite delivery vehicles that fund routine task orders over time.

Sanofi Vaccines US Inc. holds multiple named parent vehicles that anchor its federal business. Top vehicles by task order count and combined potential value include Federal Supply Schedules V797P5245X (1,779 task orders, $27 million), V797P5949X (1,341 task orders, $52.8 million), Indefinite Delivery Contract VA797P0205 (254 task orders, $29.8 million), VA797P0260 (218 task orders, $19.3 million), and V797P9170 (182 task orders, $115.1 million). The vendor also holds multiple CDC Pittsburgh indefinite delivery contracts including a $2.196 billion Vaccines for Children program vehicle (April 1, 2025–March 31, 2026), a $1.882 billion pediatric vaccines contract (April 1, 2026–March 31, 2027), adult vaccines contracts totaling $54.7 million to $118.9 million across fiscal years 2025–2027, COVID-19 vaccine vehicles ($12.7 million to $24.95 million across adult and pediatric populations), and Defense Logistics Agency influenza vaccine IDIQs worth $13.13 million to $25.06 million for the 2025–2026 and 2026–2027 flu seasons. The VA National Acquisition Center maintains single-award influenza virus vaccine contracts for the 2025–2026 and 2026–2027 seasons (approximately $113,671 and $8.67 million respectively).

Activity has fluctuated year over year: 55 awards in 2022, 153 in 2023, 117 in 2024, 59 in 2025, and 117 in 2026 through October. Eighty-eight awards with ultimate completion dates in the next twenty-four months carry a combined potential value of $101.9 million and face recompete risk. The vendor's SCI-reportable service contract activity is minimal: $14 million invoiced in FY2022 and $16.4 million in FY2024, with 0.9 and 0.8 FTEs respectively; no SCI activity recorded in FY2023. Government-paid hourly rates on SCI service contracts span a median of $7,221.10 per hour, ranging from a 10th percentile of $1,402.83 per hour to a 90th percentile of $10,742.95 per hour. SCI subcontracting engagement is zero across all prime contracts in the dataset.

The vendor's federal portfolio centers on pharmaceutical preparation manufacturing (NAICS 325412, 5,328 awards) and biological product manufacturing (NAICS 325414, 615 awards), with the bulk of activity coded to PSC 6505 (Drugs and Biologicals, 6,873 awards) and PSC 5180 (Medical and Surgical Instruments, Equipment, and Supplies, 842 awards). Sanofi Vaccines US Inc. operates as a pure prime contractor — 100% of awards are issued directly to the company with zero sub-award activity. The vendor does not pursue set-aside work and competes exclusively full-and-open across federal agencies. Its consolidated position as a critical supplier of vaccines to the CDC, Department of Defense, Department of Veterans Affairs, Department of Health and Human Services, Indian Health Service, and Bureau of Prisons reflects both established manufacturing capacity for large-scale vaccine production and regulatory compliance with FDA licensing, current good manufacturing practices, and cold-chain distribution requirements. The vendor's recompete exposure of approximately $102 million over the next twenty-four months concentrates in routine seasonal influenza vaccine contracts across federal correctional facilities and the VA system, as well as larger CDC pediatric and adult vaccine frame agreements subject to periodic re-solicitation.